Study guide
6.1 Histopathology: In Situ Carcinomas & Invasive Carcinoma Subtypes
CBCN Certified Breast Care Nurse Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CBCN Exam
CBCN Exam Facts, 2026 Blueprint & Study Plan
2 Chapter 1: Breast Health, Examination & Benign Conditions (Care Continuum)
1.1 Breast Anatomy, Vascular Supply & Hormonal Physiology 1.2 Clinical Breast Examination & Breast Awareness Education 1.3 Benign Breast Conditions, Mastalgia & Fibrocystic Changes
3 Chapter 2: Screening, Breast Density & Special Populations (Care Continuum)
2.1 Screening Modalities, Breast Density & Pharmacologic Risk Reduction 2.2 Screening & Breast Health in Special Populations
4 Chapter 3: Cancer Risk Assessment & Genetics (Care Continuum)
3.1 Proliferative Lesions, Atypia & High-Risk Benign Pathology 3.2 Breast Cancer Risk Models (Gail, Tyrer-Cuzick, Claus, BRCAPRO) 3.3 Hereditary Cancer Syndromes & Genetic Evaluation
5 Chapter 4: Patient Navigation, Surveillance & Survivorship (Care Continuum)
4.1 Patient Navigation, Barriers to Care, Social Determinants & Interprofessional Collaboration 4.2 Survivorship Care Planning, Surveillance Intervals & Recurrence Monitoring 4.3 Secondary Prevention, Physical Activity, Nutrition & Wellness Guidance
6 Chapter 5: Carcinogenesis & Diagnostic Evaluation (Diagnosis and Staging)
5.1 Carcinogenesis: How Breast Cancer Develops and Spreads 5.2 Clinical Assessment, Diagnostic Imaging & BI-RADS Categorization 5.3 Breast Biopsy Modalities & Image-Guided Localization Techniques
7 Chapter 6: Pathology, Biomarkers & Genomic Testing (Diagnosis and Staging)
6.1 Histopathology: In Situ Carcinomas & Invasive Carcinoma Subtypes 6.2 Receptor Biomarkers (ER, PR, HER2, Ki-67) & Molecular Subtypes 6.3 Multigene Genomic Assays & Recurrence Risk Stratification
8 Chapter 7: Clinical & Pathologic Staging (Diagnosis and Staging)
7.1 AJCC TNM Staging System (Anatomic vs Prognostic Staging) 7.2 Staging Workup: When to Use MRI, CT, Bone Scan & PET
9 Chapter 8: Breast Surgery, Axillary Staging & Reconstruction (Treatment Modalities)
8.1 Breast-Conserving Surgery, Margin Standards & Mastectomy Techniques 8.2 Axillary Staging: Sentinel Lymph Node Biopsy vs. Axillary Dissection 8.3 Post-Mastectomy Reconstruction & Oncoplastic Surgery
10 Chapter 9: Radiation Therapy & Chemotherapy (Treatment Modalities)
9.1 Radiation Therapy: Whole Breast, Chest Wall, Regional Nodal & Partial Breast Irradiation 9.2 Neoadjuvant vs. Adjuvant Chemotherapy Principles & Standard Regimens
11 Chapter 10: Endocrine, HER2-Targeted & Novel Systemic Therapies (Treatment Modalities)
10.1 Endocrine Therapy: SERMs, Aromatase Inhibitors, Ovarian Suppression & SERDs 10.2 HER2-Targeted Monoclonal Antibodies, Antibody-Drug Conjugates & Kinase Inhibitors 10.3 CDK4/6 Inhibitors, PARP Inhibitors & Immune Checkpoint Blockade 10.4 Trop-2 Antibody-Drug Conjugates, PI3K/AKT/mTOR Inhibitors & New Oral SERDs
12 Chapter 11: Specific Conditions & Special Populations (Treatment Modalities)
11.1 Triple-Negative Breast Cancer: Treatment Considerations 11.2 HER2-Positive Breast Cancer: Treatment Considerations 11.3 Inflammatory Breast Cancer & Paget Disease of the Nipple 11.4 Phyllodes Tumors & Breast Angiosarcoma 11.5 Treatment Considerations for Special Populations
13 Chapter 12: Symptom Management & Supportive Care (Nursing Practice)
12.1 Acute Chemotherapy Toxicities, Supportive Regimens & Oncologic Emergencies 12.2 Lymphedema Pathophysiology, ISL Staging & Complete Decongestive Therapy (CDT) 12.3 Musculoskeletal Toxicities, Bone Health & Vasomotor/GSM Relief 12.4 Complementary & Integrative Modalities 12.5 Cancer Rehabilitation: Physical, Occupational & Pelvic Floor Therapy
14 Chapter 13: Oncologic Emergencies (Nursing Practice)
13.1 Oncologic Emergencies I: Spinal Cord Compression, Hypercalcemia, Tamponade & SVC Syndrome 13.2 Oncologic Emergencies II: Hypersensitivity & Anaphylaxis, Sepsis, Pleural Effusion & Thromboembolism
15 Chapter 14: Professional Practice, Clinical Trials & Self-Care (Nursing Practice)
14.1 Professional Practice: Guidelines, Ethics, Legislation, Outreach & Accreditation 14.2 Clinical Trials in Breast Oncology 14.3 Nurse Self-Care: Compassion Fatigue, Burnout, Moral Distress & Substance Use
16 Chapter 15: Psychosocial Dimensions of Care (Psychosocial Dimensions)
15.1 Psychosocial Distress, Coping, Grief & Palliative Care 15.2 Culture, Spirituality, Sexual & Gender Identity, Age & Healthcare Disparities 15.3 Family & Caregiver Dynamics 15.4 Altered Body Image 15.5 Reproductive & Sexual Health
6.1 Histopathology: In Situ Carcinomas & Invasive Carcinoma Subtypes
Key Takeaways Explain This Topic AI
Ductal carcinoma in situ (DCIS) is a pre-invasive malignancy confined to the mammary ductal system; consensus guidelines mandate a minimum 2 mm clear surgical margin for breast-conserving therapy.
Lobular carcinoma in situ (LCIS) is hallmarked by the loss of E-cadherin expression, serving primarily as a non-obligate bilateral risk indicator rather than a direct anatomic precursor.
Invasive ductal carcinoma (IDC / NST) represents 70-80% of all invasive breast cancers and is graded via the Nottingham histologic system evaluating tubule formation, nuclear pleomorphism, and mitotic rate.
Invasive lobular carcinoma (ILC) accounts for 10-15% of cases, exhibits a distinctive single-file infiltrative growth pattern, carries higher rates of bilateral disease, and shows atypical metastatic tropism to the peritoneum, gastrointestinal tract, and ovaries.
Inflammatory breast cancer (IBC) is an aggressive clinical-pathologic entity characterized by dermal lymphatic tumor emboli presenting with rapid-onset diffuse breast erythema and peau d'orange.
Last updated: September 2026
Histopathologic classification of breast neoplasms defines tumor biology, informs prognostic staging, and establishes the foundation for systemic and locoregional treatment algorithms. Breast care nurses must understand tumor morphology, architectural growth patterns, and margin guidelines to effectively translate pathology reports for patients and multidisciplinary teams.
Non-Invasive Breast Carcinomas (Carcinoma In Situ)
In situ carcinomas represent neoplastic proliferations of epithelial cells that remain entirely confined within the basement membrane of the mammary ductal-lobular architecture, lacking the enzymatic capability to invade surrounding vascular or lymphatic stroma.
Ductal Carcinoma In Situ (DCIS)
DCIS represents approximately 20% to 25% of all mammographically detected breast malignancies, classically presenting as asymptomatic clustered pleomorphic or linear microcalcifications:
Pathophysiology : Clonal proliferation of cytologically malignant epithelial cells that fill and distend breast ducts while respecting the outer basement membrane and myoepithelial cell layer.
Architectural patterns : Histologically categorized into comedo and non-comedo patterns. The comedo subtype is characterized by central necrosis, high nuclear pleomorphism, and calcifications, representing an aggressive phenotype with a higher propensity for microinvasion. Non-comedo patterns include solid, cribriform (sieve-like fenestrations), papillary, and micropapillary.
Natural history : Regarded as a non-obligate precursor to invasive ductal carcinoma. Untreated DCIS progresses to invasive carcinoma in an estimated 20% to 50% of cases over a 10- to 15-year period.
Surgical margin standard : The Society of Surgical Oncology (SSO) and American Society for Radiation Oncology (ASTRO) consensus guidelines establish a minimum 2 mm clear negative surgical margin as the standard of care for DCIS treated with breast-conserving surgery and whole-breast radiation therapy. Margins less than 2 mm are associated with increased local recurrence and typically warrant re-excision.
Lobular Carcinoma In Situ (LCIS)
LCIS originates within the terminal duct lobular unit (TDLU) and is typically an incidental finding on core biopsy performed for unrelated imaging abnormalities:
Molecular hallmark : Complete biallelic loss of E-cadherin expression (encoded by the CDH1 gene), a transmembrane glycoprotein responsible for calcium-dependent intercellular adhesion. Its absence causes discohesive, monomorphic, round cells that loosely fill and distend lobular acini.
Clinical significance of classic LCIS : Classic LCIS is not considered a direct anatomic precursor to invasive cancer, but rather a non-obligate bilateral risk marker . It confers an approximate 1% to 2% annual risk (20% to 30% lifetime risk) of developing invasive breast cancer in either breast. Approximately two-thirds of subsequent invasive cancers are invasive ductal carcinomas rather than invasive lobular carcinomas.
Pleomorphic LCIS (PLCIS) : A distinct, aggressive variant characterized by marked nuclear pleomorphism, signet ring cells, comedo-type necrosis, and elevated Ki-67 proliferation index. Unlike classic LCIS, pleomorphic LCIS behaves biologically like high-grade DCIS and requires complete surgical excision with negative margins.
Invasive Breast Carcinoma Major Subtypes
Invasive carcinoma occurs when malignant cells breach the basement membrane and infiltrate the surrounding stroma, gaining access to blood vessels and lymphatic channels.
Invasive Ductal Carcinoma (IDC / Invasive Carcinoma of No Special Type)
Invasive ductal carcinoma (IDC), officially designated by the World Health Organization (WHO) as Invasive Carcinoma of No Special Type (NST), constitutes approximately 70% to 80% of all invasive breast cancers:
Histologic grading : Graded using the Nottingham Modification of the Bloom-Richardson system , which evaluates three morphologic features, each scored from 1 to 3 points:
Tubule and glandular formation : More than 75% of tumor forming tubules (1 point), 10% to 75% (2 points), less than 10% (3 points).
Nuclear pleomorphism : Small, uniform cells (1 point), moderate variation in size and shape (2 points), marked pleomorphism with vesicular chromatin and prominent nucleoli (3 points).
Mitotic count : Scored 1 to 3 points based on the number of mitotic figures identified per 10 high-power fields (HPF).
Combined score : Grade 1 (Well-differentiated, score 3-5); Grade 2 (Moderately differentiated, score 6-7); Grade 3 (Poorly differentiated, score 8-9).
Invasive Lobular Carcinoma (ILC)
Invasive lobular carcinoma represents the second most common histologic subtype, accounting for 10% to 15% of all invasive breast malignancies:
Histologic hallmark : Characterized by the complete loss of E-cadherin expression, resulting in small, discohesive tumor cells that infiltrate the stroma in a linear, single-file pattern. The cells permeate between collagen fibers and encircle pre-existing normal mammary ducts in concentric targetoid rings without eliciting a vigorous host desmoplastic reaction.
Diagnostic challenges : Due to the lack of desmoplasia, ILC frequently presents as an indistinct, vague palpable fullness rather than a discrete hard mass, and is notoriously difficult to detect on screening mammography, often appearing as subtle architectural distortion or remaining entirely mammographically occult.
Clinical presentation : Demonstrates significantly higher frequencies of bilateral breast involvement (10% to 20%) and multicentric or multifocal disease compared to IDC.
Metastatic patterns : Exhibits a distinct, atypical pattern of distant metastasis compared to IDC. While IDC preferentially disseminates to the lungs, liver, bones, and brain, ILC displays unique tropism for serosal surfaces, including the peritoneum, retroperitoneum, gastrointestinal tract (stomach and colon mimicking primary linitis plastica), ovaries, uterus, and leptomeninges.
Special Histological Subtypes of Breast Carcinoma
Approximately 10% of breast carcinomas display unique histological characteristics with distinctive clinical behaviors:
Tubular Carcinoma
Comprising 1% to 2% of invasive breast cancers, tubular carcinoma consists of well-differentiated, regular oval-to-round tubules lined by a single layer of low-grade epithelial cells with apical snouts and absent myoepithelial cells:
Prognosis : Exceptional overall prognosis with very low axillary nodal involvement (less than 5% to 10%).
Biomarker profile : Almost uniformly strongly estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), and HER2-negative.
Mucinous (Colloid) Carcinoma
Accounting for 2% of invasive tumors, pure mucinous carcinoma is characterized by islands and clusters of uniform, low-grade malignant epithelial cells floating within abundant pools of extracellular mucin:
Clinical features : Most common in postmenopausal women. Pure mucinous carcinoma has an indolent clinical course, low rate of regional nodal metastases, and favorable long-term disease-specific survival.
Carcinoma With Medullary Pattern (Formerly Medullary Carcinoma)
Characterized by a well-circumscribed, syncytial growth pattern of high-grade pleomorphic cells, prominent lymphoplasmacytic stromal infiltrate, and lack of tubular architecture:
Clinical paradox : Despite high histologic grade and a triple-negative (ER-/PR-/HER2-) receptor phenotype, tumors with medullary features demonstrate a paradoxically favorable prognosis with lower-than-expected rates of distant recurrence. Frequently associated with germline BRCA1 mutations. The WHO 5th edition (2019) no longer recognizes medullary carcinoma as a separate type; these tumors are classified as invasive carcinoma of no special type with a medullary pattern, a tumor-infiltrating lymphocyte-rich phenotype.
Metaplastic Breast Carcinoma (MBC)
A rare (less than 1%), aggressive subtype characterized by a mixture of malignant epithelial adenocarcinoma components with heterologous mesenchymal elements (spindle cell, squamous, chondroid, or osteoid differentiation):
Clinical behavior : Typically presents as a rapidly growing, large, palpable mass. Predominantly triple-negative, chemoresistant to standard anthracycline/taxane regimens, and exhibits a high rate of early hematogenous dissemination (particularly to the lungs) with poor overall prognosis.
Paget Disease of the Nipple
Characterized by the presence of large, intraepithelial malignant adenocarcinoma cells (Paget cells) featuring pale, vacuolated cytoplasm and prominent nucleoli within the epidermis of the nipple and areolar complex:
Clinical presentation : Presents as unilateral erythema, scaling, eczematous crusting, pruritus, or erosion of the nipple. Over 90% to 95% of cases have an underlying ductal carcinoma in situ or invasive ductal carcinoma within the lactiferous ducts.
Inflammatory Breast Cancer (IBC)
Representing 1% to 5% of all breast cancers, IBC is the most aggressive primary breast malignancy:
Pathophysiology : Defined pathologically by tumor emboli infiltrating and obstructing dermal lymphatic vessels, although dermal lymphatic invasion on punch biopsy is not strictly mandatory if classic clinical criteria are met.
Clinical hallmarks : Rapid onset (within 6 months) of diffuse erythema, warmth, induration, and peau d'orange edema involving at least one-third of the breast, often without a discrete palpable mass. Staged as cT4d (Stage IIIB, IIIC, or IV depending on nodal and distant spread).
Multimodal management : Managed aggressively with neoadjuvant systemic chemotherapy, followed by modified radical mastectomy (breast conservation is contraindicated) and post-mastectomy comprehensive chest wall/nodal radiation.
Other Prognostic Features on the Pathology Report
The CBCN outline lists prognostic features beyond histologic type and grade. Nurses should be able to explain each one:
Feature What the pathologist reports Why it matters
Lymphovascular invasion (LVI) Tumor cells inside lymphatic or blood vessels around the tumor Independent predictor of nodal spread and local recurrence; can favor regional nodal or post-mastectomy radiation in lower-stage disease
Extranodal extension (ENE) Tumor breaching the lymph node capsule into surrounding fat, often measured in mm Linked to higher nodal burden; gross or extensive ENE (for example, more than 2 mm) generally excludes omission of axillary dissection and supports nodal radiation
Proliferation index (Ki-67) Percentage of tumor nuclei staining for Ki-67 Separates low- from high-proliferation luminal tumors; values of 5% or less and 30% or more are the most reproducible cut points
Tumor size and focality Largest invasive focus; multifocal or multicentric disease Drives the T category; multiple foci are staged by the largest (with an "m" suffix)
Margins Distance from tumor to the inked surface No ink on invasive tumor; 2 mm for DCIS treated with whole-breast radiation
Tumor-infiltrating lymphocytes (TILs) Percentage of stroma occupied by lymphocytes Higher TILs predict better prognosis and chemotherapy response in TNBC and HER2-positive disease
Pathology reports follow the College of American Pathologists (CAP) synoptic protocol, so histologic type, grade, size, margins, LVI, lymph node findings, ENE, and biomarkers appear in a consistent order. Walking a patient through that template is a practical nursing skill.
Histopathologic Subtypes Comparison
Subtype Histological & Molecular Hallmarks Clinical & Radiographic Presentation Biomarker Profile Prognostic & Management Implications
Ductal Carcinoma In Situ (DCIS) Neoplastic proliferation confined by basement membrane; comedo vs. non-comedo architecture Typically asymptomatic; clustered pleomorphic microcalcifications on mammography Variable; ER+ in ~75%, HER2+ in ~30-40% of high-grade lesions Non-invasive; minimum 2 mm surgical margin for lumpectomy; excellent survival (greater than 98%)
Lobular Carcinoma In Situ (LCIS) Discohesive uniform cells filling lobules; loss of E-cadherin ( CDH1 inactivation) Incidental finding on core needle biopsy; rarely produces discrete mammographic findings Strongly ER+/PR+; HER2-negative Classic LCIS is a bilateral risk indicator (1-2% annual risk); pleomorphic LCIS excised with clear margins
Invasive Ductal Carcinoma (IDC/NST) Cohesive nests, cords, and tubules infiltrating stroma; graded via Nottingham system Palpable solitary hard irregular mass; spiculated mass on mammography/ultrasound Heterogeneous: Luminal A/B, HER2-enriched, or Triple-Negative Accounts for 70-80% of invasive cancers; prognosis governed by stage, grade, and molecular subtype
Invasive Lobular Carcinoma (ILC) Loss of E-cadherin; single-file stromal infiltration and targetoid periductal pattern Diffuse thickening or fullness; frequently mammographically occult; MRI provides superior sensitivity Typically strongly ER+/PR+; HER2-negative; low Ki-67 High rate of bilaterality (10-20%) and multicentricity; atypical metastases to peritoneum, GI tract, ovaries
Tubular Carcinoma Angulated, well-formed open tubules with apical snouts; absent myoepithelial cells Small, non-palpable spiculated mass detected on screening mammography Strongly ER+/PR+; HER2-negative Highly favorable prognosis; axillary nodal involvement rare (under 10%); standard breast conservation
Mucinous Carcinoma Islands of uniform low-grade tumor cells floating in expansive extracellular mucin pools Circumscribed, lobulated mass on ultrasound; common in elderly postmenopausal women Strongly ER+/PR+; HER2-negative Indolent course; favorable long-term survival for pure subtype; responsive to endocrine therapy
Metaplastic Carcinoma Biphasic histology with epithelial and mesenchymal differentiation (spindle, squamous, osseous) Large, rapidly enlarging, palpable mass; circumscribed dense density Predominantly Triple-Negative (ER-/PR-/HER2-) Highly aggressive; chemoresistant to standard regimens; high propensity for hematogenous lung metastasis
Paget Disease of the Nipple Large, vacuolated Paget cells infiltrating the epidermis of the nipple-areolar complex Unilateral crusting, scaling, and weeping erosion of the nipple mimicking eczema Reflects underlying tumor; frequently HER2-positive Over 90% associated with underlying DCIS or IDC; requires full-thickness wedge or punch nipple biopsy
Inflammatory Breast Cancer (IBC) Tumor emboli plugging dermal lymphatic channels on punch skin biopsy Rapid erythema, warmth, and peau d'orange involving at least one-third of the breast Often Triple-Negative or HER2-positive; high grade Highly aggressive; minimum clinical stage cT4d; treated with neoadjuvant systemic therapy, mastectomy, and radiation
Nursing Considerations in Pathology Interpretation
Nurses assist patients in understanding their pathology reports by:
Distinguishing Grade from Stage : Clarifying that histologic grade describes cellular differentiation and aggressiveness under the microscope, whereas stage reflects anatomical tumor size, nodal involvement, and distant spread.
Educating on LCIS vs. DCIS : Reassuring patients with classic LCIS that their condition is a risk marker for both breasts rather than a malignant cancer invading breast tissue, while explaining endocrine risk reduction options.
Vigilance for ILC metastatic patterns : Educating patients treated for ILC to report subtle gastrointestinal symptoms (early satiety, abdominal distension, bowel habit changes) given the atypical peritoneal and GI metastatic tropism of lobular carcinoma.